logo noventure logo noventure

TASECTAN®

0

ESPGHAN 2023

Noventure will attend the 55th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN), taking place in Vienna & Online, from May 17th to 23rd, 2023 Arrange a meeting with us to learn more about our products and license availability in the different countries. Meet us at our Stand #33! Contact us: https://noventure.com/contact-us

Read more

Launch of TASECTAN® AF in Denmark

Noventure is glad to announce the launch of TASECTAN® AF in Denmark by its partner company Pharmaforce, thus setting a record time-to-market, after Noventure granted Pharmaforce exclusive distribution right for Tasectan® AF in the Nordic markets last April. Tasectan® AF is intended to restore the physiological functions of the intestinal walls. It is specifically formulated for the control and reduction of the symptoms related to diarrheal events of different aetiologies in adults and children.

Read more

“Advantages of Gel Oral Rehydration Solutions (ORS) for the Management of Acute Diarrhea: An Update”

Piqué N, Miñana-Galbis D, Machlab S. Advantages of Gel Oral Rehydration Solutions (ORS) for the Management of Acute Diarrhea: An Update. Ann Pediatr Child Health 2020; 8(6): 1194.

We are proud to announce the publication “Advantages of Gel Oral Rehydration Solutions (ORS) for the Management of Acute Diarrhea: An Update”. This article elaborates on how a friendlier use of ORS is possible by improving palatability and texture, as well as limiting the volume per dosing. As a result, treatment compliance and, subsequently, therapeutic success, are more likely than with standard ORS preparations.

Read more

Pages

Let's meet in..

2023, Mar 10

EAU 2023

Read more

2023, May 03

EWMA 2023

Read more

2023, May 09

Vitafoods 2023

Read more

2023, May 17

ESPGHAN 2023

Read more